1884P Patient, nurse and physician preferences: Final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or On-body injector (OBI) in cancer patients

Abstract

Background: Breast cancer (BC) in young patients (<45 years) is an infrequent disease but current evidence suggest that there is an increase incidence in the last decades. After finishing adjuvant therapy, the risk of relapse or death does not increase with pregnancy. Under 40 years, fertility preservation could be an option because pregnancy after 40 usually requires in vitro fertilization techniques.

A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants

“…Each method of administration has advantages and disadvantages, with specific benefits that appeal to different patients. The availability of more than one type of administration device allows the selection of the option that best fits user needs and preferences [ 16 , 26 – 28 ]. The benefits of using an OBI to administer pegfilgrastim-cbqv are twofold: (1) patients who are unable to self-inject using a PFS or autoinjector have an alternative method for which no intervention from the patient is necessary and (2) the need for a second health care visit to receive the recommended next-day administration of pegfilgrastim-cbqv is reduced.…”

“…The benefits of using an OBI to administer pegfilgrastim-cbqv are twofold: (1) patients who are unable to self-inject using a PFS or autoinjector have an alternative method for which no intervention from the patient is necessary and (2) the need for a second health care visit to receive the recommended next-day administration of pegfilgrastim-cbqv is reduced. Additionally, use of a pegfilgrastim-cbqv OBI could improve treatment adherence rates when used in patient groups who prefer not to self-inject [ 16 , 28 ]. In a previous study of G-CSF prophylaxis, administration using an OBI compared with a PFS was associated with improved treatment adherence (94.0% [95% CI 92.9–95.2] versus 58.4% [95% CI 55.2–61.5]) [ 29 ].…”

“…In a previous study of G-CSF prophylaxis, administration using an OBI compared with a PFS was associated with improved treatment adherence (94.0% [95% CI 92.9–95.2] versus 58.4% [95% CI 55.2–61.5]) [ 29 ]. The results of one study reported adherence to the prescribed regimen as 97.6% and 63.1% for patients administered treatment with the OBI and PFS, respectively [ 28 ].…”

Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants

“…Having multiple product presentations with different delivery systems is vital to ensuring the selection of the most suitable option that fits the user needs and preferences [ 10 , 17 , 24 , 25 ]. AIs have been used for decades across a range of therapeutic areas [ 26 , 27 ].…”